Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum
- 1 September 2000
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 78 (3) , 369-372
- https://doi.org/10.1006/gyno.2000.5921
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1998
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancerInternational Journal of Gynecologic Cancer, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Lack of Vesicant Injury Following Extravasation of Liposomal DoxorubicinJNCI Journal of the National Cancer Institute, 1995
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.Journal of Clinical Oncology, 1992
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991